21 Jul 2026
Fact.MR reports that the global advanced genomics and transcriptomics sequencing services market will expand from $721.7Mn in 2026 to $1.74Bn by 2036, a 9.2% CAGR. That represents an absolute dollar opportunity of $1.02Bn. Genomics study services are moving from basic sequencing support toward complete sample handling and clear result review, as research sponsors choose providers that protect DNA and RNA quality and document each step so findings can be trusted without repeating the work.
Research organisations are outsourcing experiment design, library preparation, quality checks, data analysis, and scientific reporting as one coordinated service rather than sequencing alone. Single-cell and spatial studies are adding pressure on specimen handling, since poor cell condition or dissociation quality can weaken the final biological readout regardless of how good the sequencing run itself is.
Whole genome sequencing leads service-type demand at about 25%, giving research teams one broad assay for single-nucleotide variants, copy-number changes, and structural variants. Next-generation sequencing tops technology demand at roughly 25% on its installed workflow base and reagent ecosystem, and biomarker discovery leads application demand at close to 25% through genomic and transcriptomic comparisons across disease states. Pharmaceutical and biotechnology companies place about 30% of end-user demand.
Germany leads at a 12.4% CAGR through 2036 on large genome studies and university-hospital research, with Brazil close behind at 11.5% on population-diversity research and long-read sequencing demand. The United States follows at 10.6% on single-cell and spatial tissue-mapping projects, ahead of South Korea (9.7%), the United Kingdom (8.7%), and Japan (7.8%).
Batch effects and computational reproducibility gaps are the main brake, since a technically successful sequencing run does not always produce results that compare reliably across sites or study periods. Sample scarcity adds a second constraint, as single-cell and spatial projects face limits when tissue is small or degraded, with transit delays and unmatched collection protocols adding further risk.
Illumina and PacBio lead platform influence, with Illumina39s short-read systems used for high-sample-volume gene-change and methylation studies and PacBio39s long-read accuracy suited to larger DNA changes and repeat regions. Oxford Nanopore Technologies adds real-time, portable-to-high-output sequencing, while Novogene and Eurofins Scientific provide laboratory networks that move samples locally and support data analysis throughout the study.
Set the minimum sample amount, purity, and storage and transport rules before work begins, and use one consistent format for sample metadata across collection sites. Keep study findings separate from approved diagnostic results with a complete handling record following every sample from collection to final review, and compare software versions, batch controls, and reference databases before committing to a provider for a multi-site study.
Beyond the headline forecast, the Fact.MR study segments demand by service type, technology, application, and end user. The study also compares country-level growth across North America, Latin America, Europe, East Asia, South Asia and Oceania, and the Middle East amp Africa from 2026 to 2036. For related analysis, see Fact.MR39s coverage of cancer tumor profiling and RNA transcriptome profiling tests.
Expert analysis, actionable insights, and strategic recommendations of the highly seasoned healthcare team at Fact.MR helps clients from across the globe with their unique business intelligence needs. With a repertoire of over a thousand reports and 1 million-plus data points, the team has analyzed the healthcare industry across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.
For more information, refer to our market research report or contact the PR author.
Advanced Genomics and Transcriptomics Sequencing Services Market
Free SampleAbout Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. We are known for our syndicated research, custom research, and consulting solutions.